Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.
An advocacy group that includes the main pharmaceutical lobbying organization, PhRMA, as a member is complaining that a commercial Hims & Hers Health (NYSE:HIMS) is slated to run during the Super Bowl ...
A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...
Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...
CagriSema could still be a commercial success ... For one, semaglutide, the active ingredient in Wegovy, is being investigated in other areas with high unmet needs. Perhaps the best example ...
More and more people are taking weight loss injectables like Wegovy and Mounjaro — and though the drugs are gaining credibility when used properly, pharmacy experts are worried that not everyone ...
However, the selection of Ozempic and Wegovy for the second round of bargaining could prompt insurers in the commercial market to push for better deals for their policyholders. The high cost of ...
However, inclusion does not solve access or out-of-pocket costs issues for commercial and uninsured ... Rybelsus each goes through Medicare Part D. Wegovy, on the other hand, is eligible for ...
Wegovy is just one of the popular weight loss ... For most members with commercial insurance, the cost should reportedly be around $25 per month or less. This service also offers holistic ...
Wegovy: sales of weight loss injection more than double - The company said more than 45 million people were now ‘benefitting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback